Latest debt-to-equity ratio for Eikon Therapeutics Common Stock: 0.54 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow0.54
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
The latest debt-to-equity ratio for EIKN is 0.54. That is above the Healthcare sector average of 0.27. Investors often review this figure alongside Eikon Therapeutics Common Stock's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, EIKN currently prints 0.54 for debt-to-equity ratio, while the sector average sits near 0.27. That is roughly 103.6% above the sector mean. Large gaps often invite a closer look at Eikon Therapeutics Common Stock's growth, margins, and balance sheet.
A debt-to-equity ratio of 0.54 for Eikon Therapeutics Common Stock is not 'good' or 'bad' on its own. Compare it with the peer average (0.27) and with EIKN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting EIKN's debt-to-equity ratio (0.54), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Eikon Therapeutics Common Stock's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.